(Q34266222)

1 August 2017

1 reference

title

Review article: acid suppression in the management of gastro-oesophageal reflux disease--an appraisal of treatment options in primary care (English)

1 reference

1 August 2017

1 reference

Jones R

1

1 reference

1 August 2017

Bytzer P

series ordinal

2

1 reference

1 August 2017

language of work or name

English

0 references

publication date

1 June 2001

1 reference

Alimentary Pharmacology & Therapeutics

1 August 2017

published in

1 reference

1 August 2017

volume

15

1 reference

1 August 2017

issue

6

1 reference

1 August 2017

page(s)

765-772

1 reference

Review article: current practice and future perspectives in the management of gastro-oesophageal reflux disease

1 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2001.00985.X

Treatment of gastro-oesophageal reflux disease in adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2001.00985.X

Speed of healing and symptom relief in grade II to IV gastroesophageal reflux disease: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2001.00985.X

Updated guidelines for the diagnosis and treatment of gastroesophageal reflux disease. The Practice Parameters Committee of the American College of Gastroenterology

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2001.00985.X

Omeprazole 10 milligrams once daily, omeprazole 20 milligrams once daily, or ranitidine 150 milligrams twice daily, evaluated as initial therapy for the relief of symptoms of gastro-oesophageal reflux disease in general practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2001.00985.X

Over-the-counter histamine H2-receptor antagonists. How will they affect the treatment of acid-related diseases?

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2001.00985.X

Detection of upper gastrointestinal cancer in patients taking antisecretory therapy prior to gastroscopy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2001.00985.X

Clinical economics review: cost-effectiveness of treatment alternatives for gastro-oesophageal reflux disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2001.00985.X

Cost and Quality Effects of Alternative Treatments for Persistent Gastroesophageal Reflux Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2001.00985.X

Prognostic factors influencing relapse of oesophagitis during maintenance therapy with antisecretory drugs: a meta-analysis of long-term omeprazole trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2001.00985.X

Trends in the management of gastro-oesophageal reflux disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2001.00985.X

On demand therapy with omeprazole for the long-term management of patients with heartburn without oesophagitis--a placebo-controlled randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2001.00985.X

Three year follow up of patients with gastrooesophageal reflux disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2001.00985.X

Esomeprazole provides improved acid control vs. omeprazole In patients with symptoms of gastro-oesophageal reflux disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2001.00985.X

Symptomatic Gastroesophageal Reflux as a Risk Factor for Esophageal Adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2001.00985.X

10.1046/J.1365-2036.2001.00985.X

21 January 2018

Identifiers

DOI

1 reference

1 August 2017

1 reference